MedTrace Logo

iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML

NCT03138395 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-08-31

No results posted yet for this study

Summary

This study will use droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma mutant allele frequency (MAF) in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR.

Conditions

Interventions

DIAGNOSTIC_TEST

droplet digital PCR

This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Leylah Drusbosky, PhD · University of Florida

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-15
Primary Completion
2018-02-15
Completion
2019-08-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138395 on ClinicalTrials.gov